Refractory/Recurrent

Basic Information  

• Exatecan is also called exatecan mesylate or DX-8951F

• Exatecan is a topoisomerase-1 inhibitor with activity in varied solid and hematologic tumors

• Similar to topotecan and irinotecan

Research Results: Ewing's Sarcoma

• The phase 1 trial had 7 ES patients; 2/7 with stable disease. Source is research nurse of Dr. Demetri at Dana Farber in Boston

Research Results: non-Ewing's Sarcoma  

• 2004 abstract discussing results of a Phase III study using exatecan

• 2003 abstract discussing a 21-day continuous iv infusion method of receiving exatecan. (San Antonio, TX)

• 2003 abstract discussing Phase 1 results using a 30-minute infusion. (Oxford, UK)

Completed and Closed Clinical Trials 

• Multi-center pediatric Phase 1 trial for advanced solid tumors

• Phase 2 trial is being done at MD Anderson and MSK (and other places).

• European multi-center Phase 2 trial on young adult/adult advanced STS which doesn't allow Ewing's sarcoma